SUNESIS PHARMACEUTICALS
Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.
SUNESIS PHARMACEUTICALS
Industry:
Biotechnology Health Care Oncology Pharmaceutical
Founded:
1998-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.sunesis.com
Total Employee:
51+
Status:
Closed
Contact:
650) 266-3500
Total Funding:
221.7 M USD
Technology used in webpage:
Amazon ReCAPTCHA ReCAPTCHA V2 AWS Global Accelerator Confluence Networks Namefind Internap Bounce IO Telx Thomson Reuters Corporate Solutions
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Delcath Systems
Delcath Systems and its proprietary targeted drug delivery system are at the forefront of the regional treatment of cancer.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Viatris Biosimilars
Viatris Biosimilars is focused on the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
2013-01-01
Board_member
Current Employees Featured
William P. Quinn Chief Financial Officer and Senior Vice President, Finance and Corporate Development @ Sunesis Pharmaceuticals
Chief Financial Officer and Senior Vice President, Finance and Corporate Development
Tina Gullotta Vice President, Finance and Principal Accounting Officer @ Sunesis Pharmaceuticals
Vice President, Finance and Principal Accounting Officer
Pietro Taverna Vice President, Translational Medicine & Nonclinical Development @ Sunesis Pharmaceuticals
Vice President, Translational Medicine & Nonclinical Development
Judy Fox Chief Scientific Officer @ Sunesis Pharmaceuticals
Chief Scientific Officer
Deepali Suri Vice President, Head of Clinical Operations, Clinical Data Management and Clinical Drug Supply @ Sunesis Pharmaceuticals
Vice President, Head of Clinical Operations, Clinical Data Management and Clinical Drug Supply
2018-07-01
Dayton Misfeldt Interim Chief Executive Officer @ Sunesis Pharmaceuticals
Interim Chief Executive Officer
Mehdi Paborji Vice President, Technical Operations @ Sunesis Pharmaceuticals
Vice President, Technical Operations
Parvinder Hyare Head of Global Oncology Operations @ Sunesis Pharmaceuticals
Head of Global Oncology Operations
2015-01-01
James W. Young Non-Executive Chairman @ Sunesis Pharmaceuticals
Non-Executive Chairman
2000-01-01
Founder
Stock Details
Investors List
Bridge Bank
Bridge Bank investment in Post-IPO Debt - Sunesis Pharmaceuticals
Caxton Advantage Life Sciences Fund
Caxton Advantage Life Sciences Fund investment in Post-IPO Equity - Sunesis Pharmaceuticals
OpusPoint Partners
OpusPoint Partners investment in Post-IPO Equity - Sunesis Pharmaceuticals
Bay City Capital
Bay City Capital investment in Post-IPO Equity - Sunesis Pharmaceuticals
Alta Partners
Alta Partners investment in Post-IPO Equity - Sunesis Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Sunesis Pharmaceuticals
Merlin Nexus
Merlin Nexus investment in Post-IPO Equity - Sunesis Pharmaceuticals
Vision Capital Advisors
Vision Capital Advisors investment in Post-IPO Equity - Sunesis Pharmaceuticals
Venrock
Venrock investment in Post-IPO Equity - Sunesis Pharmaceuticals
Nextech Invest
Nextech Invest investment in Post-IPO Equity - Sunesis Pharmaceuticals
Official Site Inspections
http://www.sunesis.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 13.248.169.48
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
Sunesis.com lookup results from whois.dynadot.com server:
- Domain created: 22nd-Feb-1995
- Domain updated: 20th-May-2025
- Domain expires: 23rd-Feb-2027 1 Year, 233 Days left
- Website age: 30 Years, 133 Days
- Registrar Domain ID: 1046085_DOMAIN_COM-VRSN
- Registrar Url: http://www.dynadot.com
- Registrar WHOIS Server: whois.dynadot.com
- Registrar Abuse Contact Email: abuse@dynadot.com
- Registrar Abuse Contact Phone: +16502620100
- Name server:
- NS3.AFTERNIC.COM
- NS4.AFTERNIC.COM
More informations about "Sunesis Pharmaceuticals"
Sunesis Pharmaceuticals - Crunchbase Company Profile & Funding
Organization. Sunesis Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Sunesis is an emerging …See details»
Advisory Services - Sunesis
Sunesis executes integrated employee surveys that give the organization clear visibility into its human resources, workplace environment and overall condition. Surveys take each employee only 10 minutes, but give the corporation …See details»
Sunesis Pharmaceuticals, Inc. - LinkedIn
Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. ... Sunesis is a biopharmaceutical company focused on the development ...See details»
Sunesis Pharmaceuticals and Viracta Therapeutics Announce …
Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer.For additional information on Sunesis, please visit …See details»
Viracta Therapeutics Announces Closing of Merger with Sunesis ...
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the …See details»
Sunesis Company Profile 2024: Valuation, Investors, …
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product …See details»
Sunesis - Crunchbase Company Profile & Funding
Organization. Sunesis . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Find More Contacts for Sunesis. Protected Content. Director …See details»
Sunesis Pharmaceuticals and Viracta Therapeutics Announce
Nov 30, 2020 Management and Organization. ... Sunesis and Viracta will host a conference call and webcast today at 8:30 a.m. Eastern Time. The call can be accessed by dialing (844) 296 …See details»
Sunesis Pharmaceuticals - VentureRadar
"Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development …See details»
Sunesis Calgary for Business Success
The Sunesis team is highly trained, specialized, and talented. They work with the same values and share the vision of a more robust economy through a stronger, empowered SME sector. ... So we put together a complete toolset of business …See details»
Sunesis Pharmaceuticals - Craft
Sunesis Pharmaceuticals is focused on the R&D of oncology therapeutics for the treatment of solid and hematologic cancers. It develops QINPREZO (vosaroxin), an anti-cancer quinolone …See details»
Sunesis Pharmaceuticals Reports Second Quarter 2020
Aug 11, 2020 In July, Sunesis announced a reduction in workforce of approximately 30% to right size the organization to achieve its objectives and preserve cash resources. Announced …See details»
Home - Sunesis Holdings
Sunesis Properties specializes in land planning, entitlements, financial analysis and more. Resting on the operational capacity of Sunesis Construction, our company has the distinct advantage …See details»
Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial …
Nov 16, 2020 In July 2020, Sunesis announced a reduction in workforce of approximately 30% to right size the organization to achieve its objectives and preserve cash resources.Financial …See details»
Sunesis
Sunesis offers software modernization services that revitalize legacy systems and enable businesses to remain competitive in today’s rapidly evolving digital landscape. Our services …See details»
Sunesis DLP – Legal consultants
Welcome to SUNESIS DLP, your Trusted Partner for Comprehensive Legal Solutions. As a rapidly expanding and modern full-service law firm, we are dedicated to providing our clients …See details»
Sunesis Pharmaceuticals and Viracta Therapeutics Announce
Nov 30, 2020 --Sunesis Pharmaceuticals, Inc. and Viracta Therapeutics, Inc., a privately held precision oncology company targeting virus-associated malignancies, today announced they …See details»
Sunesis Consulting: Chaos, Risk & Resiliency
Jun 28, 2022 By Lori Caltagirone, Sunesis Consulting . During the last three years Calgary businesses have gone through a lengthy list of challenges: a lingering global pandemic, global …See details»
Sunesis Pharmaceuticals — A new BTK for a new day
Nov 16, 2017 In addition, Sunesis is moving forward with SNS-510, a PDK1 inhibitor with potential activity across multiple tumor types, and we expect a decision from Takeda on the …See details»